LABORATORY RESEARCH Loss of PTEN Stabilizes the Lipid Modifying Enzyme Cytosolic Phospholipase A2α via AKT in Prostate Cancer Cells Researchers examined whether AKT plays a role in promoting cPLA2α action in prostate cancer cells. They found a concordant increase in pAKT and cytosolic phospholipase A2α (cPLA2α) levels in prostate tissue of prostate epithelial-specific PTEN-knockout but not PTEN-wide type mice. [Oncotarget] Full Article Discovery of 1H-Indole-2-Carboxamides as Novel Inhibitors of the Androgen Receptor Binding Function 3 (BF3) A library of 1H-indole-2-carboxamides were discovered as BF3 inhibitors and exhibited strong anti-proliferative activity against both LNCaP and enzalutamide-resistant prostate cancer cell lines. [J Med Chem] Abstract Autoregulatory Feedback Loop of EZH2/miR-200c/E2F3 as a Driving Force for Prostate Cancer Development The depletion of enhancer of zeste homolog 2 (EZH2) in cell experiments inhibited prostate cancer cell growth and blocked cell cycle accompanying the downregulation of E2F3 expression. [Biochim Biophys Acta] Abstract Important Role of SUMOylation of Spliceosome Factors in Prostate Cancer Cells Using SI2 as a way of inhibiting the activity of sentrin/SUMO (small ubiquitin-like modifier)-specific proteases and the SUMO stably-transfected PC3 cells as a prostate cancer model, in combination with the stable isotope labeling with amino acids quantitative proteomic technique, scientists identified more than 900 putative target proteins of SUMO, in which 231 proteins were further subjected to bioinformatic analysis. [J Proteome Res] Abstract The Long Noncoding RNAs PCAT29 Inhibits Oncogenic Phenotypes in Prostate Cancer Prostate cancer-associated transcript 29 (PCAT29) knockdown significantly increased proliferation and migration of prostate cancer cells, while PCAT29 overexpression conferred the opposite effect and suppressed growth and metastases of prostate tumors in chick chorioallantoic membrane assays. [Mol Cancer Res] Abstract Mitogen-Activated Protein Kinase Kinase 4 (MAP2K4) Promotes Human Prostate Cancer Metastasis Researchers engineered human prostate cancer cell lines which overexpress either wild type or constitutive active MAP2K4. In vitro studies establish stable MAP2K4 overexpression promotes cell invasion, but does not affect cell growth or migration. [PLoS One] Full Article MLN2238 Synergizes BH3 Mimetic ABT-263 in Castration-Resistant Prostate Cancer Cells by Induction of NOXA The antitumor efficacy of ABT-263 and MLN2238 were evaluated as single agents and in combination in four castration-resistant prostate cancer (CRPC) cell lines: PC3, C4-2B, C4-2, and DU145. Scientists found that ABT-263 and MLN2238 alone exhibited a mild cytotoxicity, and in combination, they elicited a synergistic cytotoxic effect in CRPC cells. [Tumor Biol] Abstract The Influence of Monoacylglycerol Lipase Inhibition upon the Expression of Epidermal Growth Factor Receptor in Human PC-3 Prostate Cancer Cells It has been reported that direct activation of the cannabinoid CB1 receptor in epidermal growth factor-stimulated PC-3 prostate cancer cells results in an anti-proliferative effect accompanied by a down-regulation of epidermal growth factor receptors. Scientists investigated whether similar effects are seen following inhibition of the endocannabinoid hydrolytic enzyme monoacylglycerol lipase. [BMC Res Notes] Abstract | Full Article CLINICAL RESEARCH Fifteen-Year Survival Outcomes following Primary Androgen-Deprivation Therapy for Localized Prostate Cancer The authors determined the long-term survival impact of primary androgen-deprivation therapy (ADT) in older men with localized prostate cancer. With a median follow-up of 110 months, primary ADT was not associated with improved 15-year overall or prostate cancer-specific survival following the diagnosis of localized prostate cancer. [JAMA Intern Med] Abstract | Press Release Phase I Safety and Pharmacodynamic of Inecalcitol, a Novel VDR Agonist with Docetaxel in Metastatic Castration-Resistant Prostate Cancer Patients Scientists conducted a Phase I multicenter trial in naïve metastatic CRPC patients with escalating inecalcitol dosages, combined to docetaxel-based chemotherapy. Safety and efficacy were evaluated in groups of three to six patients receiving inecalcitol during a 21-day cycle in combination with docetaxel and oral prednisone up to six cycles. [Clin Cancer Res] Abstract Population-Based Analysis of Treatment Modalities and Survival for Clinically Localized Small-Cell Carcinoma of the Prostate Researchers determined the treatment patterns and evaluated factors affecting overall survival for patients with localized small-cell carcinoma of the prostate. [Prostate Cancer Prostatic Dis] Abstract |